Three-year interim results of overall and progression-free survival in a cohort of patients with prostate cancer (GESCAP group).
AIMS
To describe the 3-year progression-free survival (PFS), overall survival (OS) and disease-specific mortality in the prospective prostate cancer GESCAP cohort, as well as the progression to castration resistance in patients on hormone therapy.


MATERIAL AND METHODS
Prospective, observational, epidemiological, multicentre study. Of the 4087 patients recruited, 3843 were evaluable. The variables analysed were the risk group (localized, locally advanced, lymph involvement, metastatic), age, prostate-specific antigen (PSA) levels, Gleason score and initial treatment. Kaplan Meier survival analysis, the log-rank test and the Cox model were used to evaluate the survival data.


RESULTS
Three-year PFS was 81.4% and OS was 92.4%. During the 3 years of follow-up, 303 patients died (7.9%), 110 of them (36.3%) due to disease-related causes. The probability of castration resistance for all patients on hormone therapy (n=715) was 14.2%: 5%, 9.9%, 26.1% and 44.4% in localized, locally advanced, lymph involvement and metastatic cancer, respectively (log-rank P<.0001). Patients with metastases had poorer outcomes with respect to PFS, OS, disease-specific mortality and castration resistance. In the multivariate analysis, the Gleason score, PSA and presence of metastases were associated with shorter OS and PFS.


CONCLUSIONS
Our study showed stratification of risk, with a more unfavourable prognosis for patients with metastases. Patients with locally advanced disease differed with respect to those with localized disease due to their higher risk as regards disease-specific mortality. (Controlled-trials.com ISRCTN19893319).
['Cózar|J M|JM|', 'Miñana|B|B|', 'Gómez-Veiga|F|F|', 'Rodríguez-Antolín|A|A|', '|||']
D000230:Adenocarcinoma D000368:Aged D003131:Combined Modality Therapy D005500:Follow-Up Studies D006801:Humans D053208:Kaplan-Meier Estimate D008297:Male D008875:Middle Aged D000077982:Progression-Free Survival D016016:Proportional Hazards Models D011446:Prospective Studies D011471:Prostatic Neoplasms D064129:Prostatic Neoplasms, Castration-Resistant D012306:Risk D013030:Spain D016896:Treatment Outcome
Survival Prostate cancer Progression Castration resistance Cáncer de próstata Metastasis Metástasis Progresión Resistencia a la castración Supervivencia